Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX007 in Glut1 DS
NCT02599961Phase 2Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Sep 2015
- Primary completion
- Oct 2019
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Treatment-Emergent Adverse Events at 36 months. Started Sep 2015; status: terminated.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on NCT02599961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599961.